Cardiol Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Cardiol Therapeutics şirketinin toplam hissedar öz sermayesi CA$10.4M ve toplam borcu CA$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$17.5M ve CA$7.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

CA$0

Borç

Faiz karşılama oranı	n/a
Nakit	CA$15.89m
Eşitlik	CA$10.43m
Toplam yükümlülükler	CA$7.09m
Toplam varlıklar	CA$17.52m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CRDL 'nin kısa vadeli varlıkları ( CA$17.3M ) kısa vadeli yükümlülüklerini ( CA$7.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: CRDL şirketinin kısa vadeli varlıkları ( CA$17.3M ) uzun vadeli yükümlülüklerini ( CA$134.2K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CRDL borçsuzdur.

Borcun Azaltılması: CRDL un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CRDL son raporlanan serbest nakit akışına göre 7 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: CRDL serbest nakit akışı tahminlerine göre 6 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Cardiol Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Common Shares Class A Deleted from Other OTC

Recent updates

New major risk - Revenue and earnings growth

Cardiol Therapeutics Inc. to Advance CardiolRx into A Late-Stage Trial in Patients with Recurrent Pericarditis

Cardiol Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $13.5 million.

Cardiol Therapeutics Inc. has filed a Follow-on Equity Offering.

Cardiol Therapeutics Inc. Achieves Target Patient Enrollment in its Phase II Archer Trial Investigating CardiolRxTM for Acute Myocarditis

Cardiol Therapeutics Announces Completion of the Maveric Phase II Study in Recurrent Pericarditis with Results to Be Presented At the American Heart Association Scientific Sessions 2024

President recently bought US$101k worth of stock

Cardiol Therapeutics Inc., Annual General Meeting, Jul 26, 2024

Cardiol Therapeutics Inc. Announces It Has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Cardiol Therapeutics Inc. Announces Massachusetts General Hospital as the 8th Major Medical Centre Participating in MAvERIC-Pilot

New minor risk - Shareholder dilution

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Inc. Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in Model of Heart Failure with Preserved Ejection Fraction

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in Archer, A Phase II Trial of Cardiolrx™ for the Treatment of Acute Myocarditis

High number of new and inexperienced directors

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2023

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Phase II Study Evaluating Cardiolrx for the Treatment of Recurrent Pericarditis

Cardiol Therapeutics Inc. Announces the Initiation of a Phase II Open-Label Pilot Study (NCT05494788), to Investigate the Tolerance, Safety, and Efficacy of CardiolRx in Patients with Recurrent Pericarditis

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Inc. Announces Study Results Demonstrating Protective Effects of Cardiolrx in A Model of Acute Pericarditis

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating Cardiolrx Inhibits

Cardiol Therapeutics Inc. Announces First Patient Enrolled in Archer, A Phase II Clinical Trial of Cardiolrx(TM) for Treatment of Acute Myocarditis

Cardiol Therapeutics Inc. Announces Board Appointments

Cardiol Therapeutics Announces FDA Investigational New Drug Application Authorization for Multicenter Phase II Open-Label Pilot Study of Cardiolrx for Recurrent Pericarditis

Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2022

Cardiol Therapeutics Inc. Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments in Lancer Trial

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (Ind) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

Cardiol Therapeutics Common Shares Class A Deleted from Other OTC

Cardiol Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 22.0032 million.

Cardiol Therapeutics Announces First Patient Enrolled in Lancer, A Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

Cardiol Therapeutics Inc Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase Ii/Iii Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

Cardiol Therapeutics Appoints Worldwide Clinical Trials as CRO for the Company's Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with Covid-19

U.S. Food and Drug Administration Approves Cardiol Therapeutics Inc.'S Investigational New Drug Application to Commence A Phase II/III of CardiolRx

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin